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  Clinical trials of new cancer drugs should ideally include mea-
surements of parameters such as molecular target expression, 
pharmacokinetic (PK) behavior, and pharmacodynamic (PD) 
endpoints that can be linked to measures of clinical effect. 
Appropriate PK/PD biomarkers facilitate proof- of-concept 
demonstrations for target modulation; enhance the rational 
selection of an optimal drug dose and schedule; aid decision-
making, such as whether to continue or close a drug develop-
ment project; and may explain or predict clinical outcomes. In 
addition, measurement of PK/PD biomarkers can minimize 
uncertainty associated with predicting drug safety and effi -
cacy, reduce the high levels of drug attrition during develop-
ment, accelerate drug approval, and decrease the overall costs 
of drug development. However, there are many challenges in 
the development and implementation of biomarkers that 
probably explain their disappointingly low implementation  in 
phase I trials. The Pharmacodynamic/Pharmacokinetic Tech-
nologies Advisory committee of Cancer Research UK has 
found that submissions for phase I trials of new cancer drugs 
in the United Kingdom often lack detailed information about 
PK and/or PD endpoints, which leads to suboptimal informa-
tion being obtained in those  trials or to delays in starting the 
trials while PK/PD methods are developed and validated. 
Minimally invasive PK/PD techno logies have logistic and 
ethical advantages over more invasive  technologies. Here we 
review these technologies, emphasizing magnetic resonance 
spectroscopy and positron emission tomography, which pro-
vide detailed functional and metabolic information. Assays 
that measure effects of drugs on important biologic pathways 
and processes are likely to be more cost-effective than those 
that measure specifi c molecular  targets. Development, valida-
tion, and implementation of minimally invasive PK/PD meth-
ods are encouraged.  [J Natl Cancer Inst 2006;98:580 – 98] 
 Anticancer drug discovery and development are undergoing a 
period of rapid and unprecedented change  ( 1 , 2 ) . Molecular biol-
ogy and genomic approaches have led to an increasingly detailed 
understanding of the genetic abnormalities that drive the malig-
nant phenotype  ( 3 ) . The identifi cation of cancer-causing genes 
and the cellular pathways that their encoded proteins control pro-
vides a wide range of new targets for oncology drug discovery 
and development  ( 1 , 2 , 4 ) . At the same time, the pace of drug dis-
covery and development is being accelerated by numerous inno-
vative technologies, particularly high-throughput methodologies 
for genomics, screening, structural biology, pharmacokinetics, 
and combinatorial chemistry  ( 1 , 5 ) . 
 The nature of the drugs emerging from these new approaches 
is also changing dramatically. The previous generation of anti-
cancer agents was dominated by cytotoxic drugs, whose precise 
molecular mechanisms of action were often not clear during their 
preclinical and early clinical development. The new generation 
of molecular therapeutics include mechanism-based modulators 
of proliferative signal transduction and cell cycle transit, telo-
mere regulation, apoptosis/survival, invasion, angiogenesis, and 
metastasis  ( 1 – 4 ) . Clinical development of such agents is still in 
the early stages, but the promise of this approach has already 
been shown through the regulatory approval of trastuzumab, a 
humanized monoclonal antibody for ErbB2-positive breast 
 cancer  ( 6 ) ; imatinib mesylate, a Bcr-Abl and c-Kit inhibitor in 
chronic myelocytic leukemia  ( 7 ) and gastrointestinal stromal 
 tumors  ( 8 ) ; and the epidermal growth factor receptor tyrosine 
 kinase inhibitors gefi nitib and erlotinib, which show preferential 
activity in non – small-cell lung cancers that harbor activating 
 kinase mutations  ( 9 , 10 ) . Other recently approved molecular thera-
peutic agents include the monoclonal antibody cetuximab for 
colorectal cancers that overexpress the epidermal growth factor 
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receptor  ( 11 ) and the monoclonal antibody bevacizumab, which 
acts on the vascular endothelial growth factor receptor ligand, 
VEGF-A  ( 12 )  . Many other innovative drugs that interfere with 
the molecular pathology of human cancers are now undergoing 
preclinical and clinical development  ( 13 ) . However, based on 
past experience, the vast majority of these drugs will not make it 
through to marketing approval  . 
 The new molecular therapeutics pose a considerable challenge 
for oncology drug development [reviewed in  ( 14 ) ]. For preclini-
cal and clinical development, it is essential to know 1) whether 
adequate or optimal exposures are being achieved in the tissues 
of interest in the experimental organism or patient, 2) whether the 
molecular target is being appropriately modulated, and 3) whether 
the desired biologic effect is being obtained ( Fig. 1 ). The ability 
to make these types of measurements as part of phase I/II clinical 
trials is particularly important. For example, in phase I trials, it is 
no longer suffi cient only to defi ne the nature of the dose-limiting 
toxicity, the maximum tolerated dose, and the recommended 
dose for a phase II trial. Phase I trials are increasingly extensions 
of the preclinical mechanistic drug development process and, as 
such, represent the fi rst clinical test of the hypothesis. The devel-
opment of techniques to measure pharmacokinetic (PK) and 
pharmacodynamic (PD) endpoints is essential for both the pre-
clinical and clinical development of the new oncology drugs 
 ( 15 , 16 ) . Here we use the term  PK to denote what the body does 
to the drug in terms of its absorption, distribution, metabolism, 
and excretion, including the concentration – time relationship and 
its dependence on dose; the term  PD is used to denote what the 
drug does to the body. PK/PD relationships refl ect the connection 
between the two. Linkage of information on the status of the mo-
lecular target, PK, and PD to measures of biologic and clinical 
effects constitutes a pharmacologic  “ audit trail ”  ( 17 ) . 
 Throughout the process of preclinical and clinical drug devel-
opment, measurement of appropriate biomarkers is invaluable to 
aid the selection of the most appropriate clinical candidate, to 
provide demonstration of proof of concept for molecular and bio-
logic mechanisms, to help the interpretation of clinical trial data, 
to inform the identifi cation of   the optimal dose and schedule, and 
to support regulatory  submissions  ( 18 , 19 ) . PK/PD biomarkers 
should help to minimize risks associated with studies of drug 
safety and effi cacy and  reduce the levels of drug attrition in pre-
clinical and clinical phases, which are unacceptably high. Hence, 
the cost of pharmaceutical development should be decreased. 
 Developing and implementing PK/PD biomarker methods can 
be challenging because they need to be sensitive and specifi c and 
may be very complex. There are also issues concerning the inva-
siveness of these technologies and their logistic impact on the 
conduct of early clinical trials. Although PK/PD endpoints clearly 
add value to preclinical drug development and early clinical tri-
als, it is important that the introduction and implementation of 
PK/PD methodologies should not delay such trials. These chal-
lenges may explain results of a recent survey showing that the 
use of molecular and functional imaging endpoints within phase 
I trials of molecular therapeutics was disappointingly low  ( 20 ) . 
 The Pharmacodynamic/Pharmacokinetic Technologies Advi-
sory Committee (PTAC) was established under the auspices of 
the Phase I/II Clinical Trial Committee and the New Agents 
Committee of Cancer Research UK. The latter committee is re-
sponsible for reviewing and auditing applications for phase I and 
II trials of new agents in the United Kingdom  ( 21 ) . While re-
viewing new drug applications, PTAC members recognized that 
there was a need for 1) greater awareness of PK/PD endpoints in 
the oncology drug development community, 2) more extensive 
implementation of PK/PD endpoints in preclinical and clinical 
anticancer drug development, and 3) more research to bring for-
ward improved PK/PD technologies for the future. In particular, 
the sponsoring Cancer Research UK committees have noted that 
submissions of new agents frequently lacked information on PK/
PD endpoints in the clinical trial. Such omissions could lead to 
suboptimal information being obtained in the trials that are ap-
proved or to delays in implementing the trials while appropriate 
PK/PD endpoints are developed. Discussions with other drug 
 development organizations, such as the European Organization 
for Research and Treatment of Cancer (EORTC) and the U.S. 
National Cancer Institute indicate that the lack of or use of weak 
PK/PD endpoints is common. PTAC appears to be the only ad-
visory body worldwide to provide comprehensive multidisci-
plinary advice in this area. 
 PTAC members are experts who have experience with the key 
PK/PD methodologies and consult with other specialists when 
appropriate. Our goal with this review is to publish the Commit-
tee’s emerging experience and recommendations so that they can 
be of more general benefi t beyond the Cancer Research UK orga-
nization  . The Committee welcomes feedback from other orga-
nizations and investigators with regard to their experience of 
PK/PD issues in phase I and II trials. The development and shar-
ing of broad guidelines for PK/PD endpoints seem particularly 
appropriate given the changing nature of early clinical trials, the 
uncertainty and risk associated with the new range of molecular 
therapeutics, and the need for extensive cooperation between ac-
ademia and the pharmaceutical and biotechnology sectors  ( 19 ) . 
 A wide range of invasive and minimally-invasive techniques 
are available to determine  PK and PD endpoints. Judicious use of 
biopsy or other invasive surrogate-based assays to measure PK 
and PD, including target modulation, remains very important in 
early clinical trials. However, because of the logistic and ethical 
issues associated with invasive measurements, there is an in-
creasing requirement for minimally invasive assays   ( 22 ) . Here 
we review the various imaging-based minimally invasive meth-
odologies available for assessing PK/PD endpoints and discuss 
their strengths and weaknesses ( Table 1 ). We emphasize  magnetic 
 Fig. 1.  Stages in preclinical and clinical therapeutic development showing paired 
objectives and examples of measurable endpoints. 
Objectives Measurable endpoints
Patient selection Expression of molecular target (e.g.,
erbB2), physiologic state (e.g., hypoxia)
Achievement of the necessary
concentrations for activity at the site of
action  
Pharmacokinetic properties in plasma
and/or tissue
Specific action on the molecular target
or pathway  
Target inhibition in tumors and/or
surrogate normal tissue  
Induction of the desired biologic effect Inhibition of proliferation, cell cycle
transit, invasion, angiogenesis, metastasis
or telomere erosion; or induction of
apoptosis, differentiation or senescence    
Resulting clinical response Tumor regression, cytostasis
Patient outcome Disease-free survival, performance status,
quality of life, overall survival 
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resonance imaging (MRI), magnetic resonance spectroscopy 
(MRS), and positron emission tomography (PET) because they 
provide the greatest level of functional and metabolic informa-
tion. We also highlight the current limitations in PK/PD technol-
ogies, particularly in terms of their ability to measure effects on 
specifi c molecular targets or biologic functions. Finally, we iden-
tify areas of current need and make recommendations for further 
research.  
 C OMPUTED T OMOGRAPHIC S CANNING 
 X-ray computed tomography (CT) scanning, the most widely 
employed method of transaxial imaging, is used in the diagnosis 
and staging of most soft-tissue and bone cancers and in the 
 assessment of response  ( 23 ) . CT scanning provides excellent 
soft-tissue contrast, allowing visualization of disease in three 
 dimensions. Although CT has been the benchmark method of im-
aging soft-tissue disease for many years, its use for some applica-
tions is now being eclipsed by MRI  ( 24 ) . In PD studies, CT is 
used mainly to measure changes in the volume of disease with 
treatment  ( 25 ) . CT measurement of changes in disease volume is 
usually performed to support bidimensional assessments of re-
sponse as recommended by the Union Internationale Contre le 
Cancer (UICC)  ( 26 ) or unidimensional assessment of response, 
as recommended by Response Evaluation Criteria in Solid Tu-
mors (RECIST)  ( 27 ) , although its multislice capability also al-
lows accurate assessment of tumor volume. CT can also be used 
with X-ray – dense contrast agents, such as iodinated materials, to 
assess some of the functional properties of tumors. Contrast 
agents have also been used to assess tumor perfusion  ( 28 ) and are 
routinely used to defi ne perfused areas of tissue and areas of 
blood – brain barrier breakdown. CT can also be helpful in deter-
mining the boundaries  of the tumor and the extent of its invasion 
into adjacent tissues and can identify involvement of lymph 
nodes, particularly when such involvement has caused an in-
crease in lymph node size or an abnormal lymph node appear-
ance   ( 23 ) . In clinical trials of innovative therapies, CT is most 
commonly used to assess the size of the primary tumor and the 
extent of metastatic disease. 
 U LTRASOUND S CANNING 
 Ultrasound is a relatively inexpensive means to obtain sec-
tional images of tissue  ( 29 ) . High-frequency sound is transmitted 
from a transducer that is placed in contact with the skin surface  . 
Refl ected or scattered sound is received back at the transducer, 
allowing images of scatter intensity to be reconstructed so that 
tissues are visualized in real time. Ultrasound is not readily trans-
mitted through bone and is refl ected strongly at air – tissue inter-
faces. Thus, this technique is limited to tissues that are not 
overlaid by bone or that are accessible through an ultrasound 
window. In addition to depicting tumor by contrast to other soft 
tissues, ultrasound scanning can distinguish tumor from fl uid-
fi lled compartments, such as cysts. Doppler ultrasound  techniques 
have a high sensitivity for measuring blood fl ow. Current devel-
opments in ultrasound technologies include three-dimensional 
ultrasound imaging techniques  ( 30 ) and the use of ultrasound 
contrast agents, which show promise in assessing vascular deliv-
ery of agents. Although ultrasound is of considerable assistance 
in diagnosis, its use for morphologic assessment in serial studies 
is limited because the technique is operator dependent, which 
makes it diffi cult to reproduce imaging planes. Color Doppler 
ultrasound measurements  ( 31 ) have been used to assess tumor 
response to conventional therapies; as with other modalities, con-
trast agents may also prove helpful  ( 32 ) . The major application of 
ultrasound in therapeutic trials is to assess changes in tumor size. 
Ultrasound scanning using microbubble contrast agents has 
 potential value in the measurement of perfusion in response to 
antivascular and antiangiogenic agents  ( 33 , 34 ) . 
 M AGNETIC R ESONANCE T ECHNIQUES 
 MRI and, to a lesser extent, MRS are beginning to have im-
portant roles in anticancer drug trials. MRI is routinely used in 
the initial evaluation of tumor size, shape, and anatomic appear-
ance, and changes in these parameters during therapy can be used 
to assess and quantify the PD effects of a drug. In addition, dy-
namic contrast-enhanced MRI (DCE-MRI) is proving increas-
ingly valuable for assessing PD endpoints  ( 35 ) . Other MRI 
approaches, as well as MRS, also have PD applications, and in 
some cases MRS can even be used for minimally invasive moni-
toring of anticancer drug uptake and metabolism. Almost all 
 major hospitals in the developed world have access to MRI in-
struments for routine use, and such instruments are already 
widely used in drug trials for morphologic estimation of tumor 
size. Because MRI (including DCE-MRI and diffusion-weighted 
MRI) uses the isotope  1 H, most MRI instruments with a fi eld 
strength of 1.5 – 3 T currently in clinical service can easily be 
adapted to perform  1 H MRS. By contrast, MRS studies with the 
natural isotopes  31 P or  19 F require broad-band systems, which are 
currently available only at research centers. 
 The high concentration of  1 H present in tissue water (80 – 90 M) 
enables magnetic resonance images to be obtained. MRI is now 
the method of choice for diagnostic imaging of tumors in 
many areas of the body. Although MRI does not directly show 
bone, it can, unlike CT, be used to obtain images directly in arbi-
trary orientations or in three dimensions, without being limited 
by radiation dose. MRI also often provides better soft-tissue 
contrast than other methods because the measurements can be 
manipulated to provide a wide range of contrasts for given 
tissues. Centers with MRS facilities routinely use both MRS and 
MRI in combination in the clinic and increasingly in the laboratory 
to defi ne a volume from which chemical information is then 
obtained. 
 Magnetic Resonance Imaging 
 MRI provides excellent information on morphology and is 
useful for defi ning tumor location, for detecting and measuring 
the extent of local invasion, and for detecting  more distant dis-
semination. Increasingly, MRI also provides a range of functional 
measures of physiology and the local tissue matrix  ( 36 ) . 
 MRI contrast agents, which have magnetic properties that 
change the image signal intensity, provide an important means of 
obtaining functional information and facilitate the morphologic 
evaluation of tumors. Contrast agents constitute a rapidly devel-
oping fi eld in MRI  ( 36 – 38 ) , which we will not review here in 
detail; instead, we focus on methods used in drug trials. At pres-
ent, the main contrast agents licensed for use in patients are 
 gadolinium-based (e.g., gadolinium diethyltriaminepentaacetic 
acid [Gd-DTPA]). Gd-DTPA is a low-molecular-weight contrast 
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agent in routine clinical use for enhancing the visibility of lesions 
in magnetic resonance images. Its effects are particularly clear 
for brain lesions because, although the agent does not cross the 
normal blood – brain barrier, it can leak out of abnormal vessels 
present in tumors  ( 39 , 40 ) . Judgments about the nature and size of 
a lesion are based on a qualitative assessment of altered contrast 
agent uptake compared with the surrounding normal tissue. These 
MRI examinations have evolved from simple comparisons of im-
ages taken before and after injection of a contrast agent to evalu-
ations of sets of images obtained every few seconds following 
injection (DCE-MRI). These serial evaluations have led in turn 
to a variety of quantitative methods for assessing the kinetics of 
the contrast agent in the tumor that are already being widely ap-
plied in drug trials ( Fig. 2, A and B ). The kinetic parameters de-
rived from such measurements depend on tumor perfusion and 
on the permeability – surface area (PS) product of the tumor blood 
vessels for the contrast agent  ( 41 , 42 ) ; when tumor perfusion is 
very high and the PS product is low, the parameter  K trans (volume 
transfer constant between blood plasma and extravascular extra-
cellular space) is similar to the PS product, and when tumor per-
fusion is low and the PS product is high, the behavior of  K trans is 
dominated by fl ow. Tumors typically show high inter- and intra-
variability with respect to whether  K trans is dominated by fl ow or 
perfusion. These properties may be analyzed on the basis of mean 
changes within a defi ned region of interest or by using pixel- 
by-pixel mapping of properties throughout the tumor  ( 43 , 44 ) . By 
examining changes during the fi rst pass of the agent through the 
vascular bed, it is possible to obtain information on relative blood 
volume and perfusion  ( 45 , 46 ) . 
 Despite uncertainties about the precise physiologic interpreta-
tion of parameters derived from DCE-MRI, its wide availability 
for both clinical and preclinical research has led to considerable 
interest in its use for the evaluation of tumor vasculature before 
and after treatment. Recommendations for the use of DCE-MRI in 
the evaluation of novel antiangiogenic and antivascular therapeu-
tics have recently been published  ( 47 , 48 ) . Large-molecular-weight 
contrast agents (often used as  “ blood-pool ” agents), such as ferric 
oxide particles coated in dextran  ( 49 ) and Gd-based cores linked 
to dendrimers to increase the hydrodynamic radius  ( 50 ) , are being 
introduced. The clinical use of these agents has been driven by the 
needs of diagnostic radiology (for example, as a way to visualize 
lymph node involvement and to enhance magnetic resonance an-
giography), but quantitative approaches yield important parame-
ters such as vascular volume and the permeability of tumor vessels 
to such large particles  ( 51 , 52 ) . These agents have not yet been li-
censed for clinical blood pool or permeability studies. In parallel 
with the introduction of these macromolecular agents for clinical 
use, preclinical studies have used gadolinium-labeled albumin to 
provide similar kinds of information  ( 53 ) .  Although quantitative 
MRI assessments of tumor vasculature with blood pool agents are 
in their infancy, the parameters they provide may have a less 
ambiguous physiologic interpretation than those obtained from 
Gd-DTPA uptake kinetics. Overall, DCE-MRI provides a range 
of powerful techniques to detect PD changes in treated tumors, 
especially changes related to the vasculature. 
 Studies of dynamic contrast agents that assess vascular per-
meability and/or blood fl ow are rapidly developing as important 
methods of assessing PD endpoints in, for example, patients with 
bladder, bone, or soft-tissue cancers   ( 54 – 58 ) . DCE-MRI has been 
incorporated into phase I clinical trials of the antivascular agents 
5,6-dimethylxanthenone-4-acetic acid  ( 59 ) , combretastatin-A4-
phosphate  ( 60 ) , and ZD6126  ( 61 ) . In these trials, a  decrease in 
the kinetics of contrast agent uptake in patients who received 
relatively high doses of drugs was interpreted as a reduction in 
blood fl ow. DCE-MRI has also been shown to provide a good 
measure of response in patients receiving androgen-inhibiting 
treatment for prostate cancer  ( 62 ) , and it has been used to assess 
responses to primary medical therapy in breast cancer  ( 63 ) . 
 Vascular permeability, an important parameter monitored by 
DCE-MRI, is a characteristic of angiogenesis because the VEGF-
dependent neovasculature is characteristically leaky. The marked 
reduction in kinetics of contrast agent uptake observed in pros-
tate cancer is believed to result from inhibition of VEGF 
 Fig. 2.  Measuring angiogenic and vascular change. Magnetic resonance images 
of a grade 2 infi ltrating lobular breast cancer in a 49-year-old patient before ( A ) 
and after ( B ) treatment with cyclophosphamide and doxorubicin.  Left panels : 
images of  K trans scaled to a maximum of 1 min  − 1 where  K trans is displayed using a 
color scale in which low values are dark blue and high values are yellow (absence 
of color indicates no value fi tted);  right panels : two-dimensional gradient echo 
subtraction images showing areas of contrast enhancement in white. Courtesy of 
Dr. A. Padhani, The Institute of Cancer Research and Royal Marsden Hospital. 
 C ) Coronal sections showing the distribution of  124 I-labeled anti-vascular 
endothelial growth factor (VEGF) receptor antibody (low uptake,  dark red ; high 
uptake,  white ) given concurrently with the phase I treatment in a patient with 
metastatic colorectal cancer (imaging at 24 hours after treatment). Reproduced 
by permission of Oxford University Press from Jayson et al.  (134) . 
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by androgen blockade. DCE-MRI techniques have also been 
employed in several hypothesis-driven phase I clinical trials of 
new antivascular and antiangiogenic therapeutics  ( 59 – 61 , 64 ) . A 
strength of DCE-MRI is that it allows the whole tumor, or a sec-
tion through it, to be characterized either on a pixel-by-pixel ba-
sis or by evaluation of the mean parametric change for a defi ned 
region of interest. Histogram analysis of the pixel-by-pixel data 
has proven helpful for analyzing responses in heterogenous tu-
mors, although more sophisticated analytic approaches are being 
developed. It is likely that assessment of perfusion will also be 
helpful for some tumors, particularly those in the brain, where 
changes that precede the blood – brain barrier breakdown or that 
follow its repair may be informative. DCE-MRI techniques may 
be particularly useful in assessing the likelihood of a therapeutic 
agent reaching tumor cells. 
 One new MRI approach that is being used to assess tumors in 
vivo involves the attachment of functional contrast agents to spe-
cifi c ligands or targeting moieties  ( 65 ) . An alternative approach 
uses contrast agents designed so that they act as a substrate for an 
existing cellular process or can be activated in situ, for example, 
by being designed as a substrate for a specifi c enzyme  ( 66 – 69 ) . 
This promising area of research may yield new PK endpoints, 
although currently developments are at the early preclinical stage. 
MRI would benefi t from the availability of more specifi c agents 
that target identifi ed cellular processes  . 
 Diffusion-weighted MRI does not involve administration of a 
contrast agent but can be used to measure parameters associated 
with the rate and distance of water molecule diffusion  ( 70 ) that 
may refl ect drug access  ( 71 ) . Both diffusion-weighted MRI and 
DCE-MRI may indicate changes in tumor anatomy and physiol-
ogy during therapy. 
 Magnetic Resonance Spectroscopy 
 MRS is the only noninvasive in vivo method for chemically 
distinguishing between, and measuring the concentrations of, bio-
chemical compounds (or drugs and their metabolites), and it is 
beginning to have applications in drug trials. Instead of providing 
an anatomic image, MRS data are usually visualized in the form 
of a spectrum, in which the peaks correspond to different chemi-
cals  ( 72 ) , although low-resolution spatial images corresponding 
to different chemical concentrations can also be produced. Thus, 
MRI techniques can be used to defi ne a volume in a tumor (or in 
normal tissue) and MRS can then be used to measure the concen-
tration of endogenous biochemical compounds (or drugs) in that 
volume in real time. Most of the early work on human tumors 
other than brain or prostate tumors  ( 73 ) was performed using 
 31 P-MRS. However, in recent years there has been much interest 
in the use of  1 H-MRS for breast  ( 74 ) , cervical  ( 75 ) , and other 
tumors because of its better sensitivity and, consequently, spatial 
resolution compared with  31 P-MRS  ( 72 ) . 
 PD studies can use MRS to measure the concentration of 
 endogenous metabolites, such as adenosine triphosphate (ATP), 
phosphomonoesters (e.g., phosphocholine), or inorganic phos-
phate ( Table 1 ); intracellular pH (with the use of  31 P-MRS); or 
the concentrations of lactate, choline compounds, inositol com-
pounds, creatine compounds, and glutamine/glutamate (with the 
use of  1 H-MRS). Many PD studies have been performed using 
animal tumor models, usually with the use of  31 P-MRS. Animal 
tumor models often display large changes in energy metabolism 
during therapy, something that is rarely seen in tumors in pa-
tients. However, clinical  31 P-MRS studies in many tumor types, 
notably non-Hodgkin lymphoma  ( 76 ) and breast cancer  ( 77 , 78 ) , 
have shown that changes in the phosphomonoester peak are as-
sociated with response to treatment and that these changes may 
be a marker for changes in proliferation ( Fig. 3, A and B ). Other 
studies in cultured cells and animal models have shown that tu-
mor cells display marked changes in the MRS spectrum as they 
undergo apoptosis ( Fig. 4, A and B )  ( 79 – 81 ) . Additional studies 
have investigated the effectiveness of  1 H-MRS in assessing re-
sponse. For example, two studies  ( 82 , 83 ) found that a decrease in 
total choline (a composite signal derived predominantly from 
choline-containing compounds) was associated with response to 
chemotherapy in glioma — specifi cally, with changes in perme-
ability and size ( Fig. 3, C and D ). In another study, a decrease in 
total choline was associated with response to chemotherapy in 
lymphoma and germ cell tumors  ( 84 ) . 
 Other in vivo PD magnetic resonance methods are used to 
measure hypoxia, oxygenation, and glucose utilization. Hypoxia 
can be measured by using a fl uorinated hypoxia-imaging agent, 
such as SR-4554, which has low toxicity and is currently under-
going clinical trials ( Fig. 5, A )  ( 85 – 87 ) . Oxygenation can be 
measured by using organofl uorine compounds that have a high 
affi nity for oxygen, such as perfl uorocarbons; however, several 
problems (including nonuniform delivery and distribution within 
tumors) currently preclude their clinical use. Tumors are highly 
glycolytic, and this property has permitted their detection and 
staging by using PET images of  18 F-fl uorodeoxyglucose ( 18 FDG). 
Changes in  18 FDG metabolism can be an early indicator of tumor 
response. MRS of  19 FDG  ( 88 ) and  13 C-glucose  ( 89 ) has also been 
used in research settings to detect various aspects of glucose 
uptake and metabolism. 
 For PK studies, it is possible, in principle, to monitor drug con-
centrations in the tumor, liver, kidney, and other major organs 
where the drug may accumulate ( Fig. 6, A – D )  ( 90 – 92 ) . Thus, drug 
retention, metabolism, and elimination can be studied in the target 
tissue by using MRI techniques to defi ne a volume within a tumor 
(or in normal tissue), followed by MRS to measure the concentra-
tion of the drug and its metabolites in real time. The advantage of 
this approach is that nothing (other than the drug) is administered, 
no samples are taken, and no ionizing radiation is used. 
 The molecular structures of certain agents (e.g., the presence 
of a nucleus with an easily detected MRS signal) enable PK stud-
ies of parent drugs and metabolites using direct detection by MRS. 
For example, the fl uorine atom has very high magnetic resonance 
sensitivity (83% that of the most sensitive stable nucleus,  1 H), and 
there is no background fl uorine signal in living tissue. Fluorine-
containing drugs such as 5-fl uorouracil (5FU), one of the most 
widely used anticancer agents, are thus particularly well suited to 
MRS studies, many of which have been performed in animals and 
patients. So far, studies in patients have been restricted to 5FU, its 
prodrug, capecitabine, and the difl uorinated drug gemcitabine 
using  19 F-MRS  ( 93 – 95 ) , and to ifosfamide and cyclophosphamide 
using  31 P-MRS  ( 96 ) . The elimination rate of 5FU from tumors in 
patients is associated with response, allowing an early prediction 
of the likely success or failure of a treatment regimen  ( 93 ) . It has 
recently become possible to routinely detect fl uoronucleotides, 
the active species of 5FU that are formed in the tumor cell, in 
1.5-T  19 F spectra  ( 97 ) . 
 MRS can also be used to detect endpoints in antibody-
directed, protein-directed, and gene-directed enzyme prodrug 
therapy. For example, MRS using the  19 F-containing drugs 
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5-fl uorocytosine and gemcitabine can be used to determine the 
success or failure of gene or protein delivery  ( 98 )  . 
 Other nuclei that will be useful in the study of anticancer drug 
PK are  1 H [which has thus far only been used to detect iproplatin 
in mice  ( 99 ) ] and  13 C  ( 100 ) . The latter nucleus differs from previ-
ously mentioned nuclei in that it is present only in very small 
amounts (i.e., 1.1%) in natural carbon; thus, it is necessary to 
synthesize a  13 C-labeled sample of the drug (note that  13 C is not 
radioactive). In this respect, this particular MRS approach resem-
bles PET, in which synthesis of drug analogs containing radio-
nuclides is required  (see next section). 
 MRS has two advantages compared with imaging methods 
that use radiolabels. First, with MRS, it is often possible to dis-
tinguish between the substances that give rise to the signals, 
which permits minimally invasive monitoring of drug metabo-
lism in the tumor. In principle, this MRS method can allow for 
more complete PK modeling, for example, by identifying routes 
of excretion  ( 101 ) . Thus, novel anticancer drugs can fi rst be as-
sessed in preclinical experiments, in which drug metabolites can 
be identifi ed and assigned, modeling applied, mechanisms of 
 action clarifi ed, and suitable clinical protocols designed. By con-
trast, with fl uorine- or phosphorus-containing agents the native 
drug is used for MRS and hence synthesis of a labeled analog is 
not required. In principle, it should be possible to detect almost 
any drug if it is labeled with  13 C; however, because  13 C-labeled 
precursors are expensive, and every molecule of the drug must 
contain the label, the routine use of tracer doses is not feasible. 
Thus far, the only study of a  13 C-labeled drug has been of temo-
zolomide in mice  ( 100 ) . 
 The major limitation of MRS for PK is its lack of sensiti-
vity ( Table 1 ); in general, only drugs given in quantities of 
 approximately 0.5 g/m 2 can be detected. Thus, PK studies, even 
 Fig. 3.  Assessing response via metabolic change.  A ) Localization image for  31 P 
magnetic resonance spectroscopy showing a single voxel positioned over a breast 
tumor.  B )  31 P magnetic resonance spectra obtained from the region defi ned in 
 A before (pretreatment), during (week 5 and week 20), and after (week 31) a 
course of chemotherapy, showing an initial increase in all metabolites (week 
3) followed by a marked reduction in metabolite signals with treatment (weeks 
20 and 31). Reproduced with permission from Leach et al.  ( 77 ) , copyright John 
Wiley and Sons Limited.  C ) Pretreatment fl uid-attenuated inversion recovery 
( top ) and T2-weighted fast spin-echo ( bottom ) images from a patient with low-
grade glioma receiving treatment for recurrent disease, showing the position 
of voxels selected for spectroscopy.  D ) Serial  1 H spectroscopy measurements 
from the same patient  showing long echo time (TE =135 ms) stimulated-echo 
acquisition mode spectra obtained before ( a ) and at ( b ) 3 months, ( c ) 6 months, 
and ( d ) 9 months after initiation of temozolomide treatment. Within both series, 
a progressive decrease in the choline/creatine (Cho/Cre) ratio was observed, 
suggesting reduced membrane metabolism and diminishing cellular density. 
Also note the increasing conspicuity of the N-acetylaspartate (NAA) peak, a 
specifi c neuronal marker whose level may refl ect the regression of tumoral 
tissue and repopulation of normal brain matter. First published in Murphy et al. 
 ( 83 ) .  E ) In vitro  31 P magnetic resonance spectra of cell extracts obtained from 
human colon adenocarcinoma HT29 cells treated with the Hsp90 molecular 
chaperone inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) ( top ) 
or with vehicle ( bottom ).  F ) In vivo  31 P magnetic resonance spectra of a 
HT29 tumor xenograft before ( top ) and after ( bottom ) 17AAG treatment. 
Reproduced by permission of Oxford University Press from Chung et al.  ( 106 ) . 
 G ) Fluorodeoxyglucose positron emission tomography (FDG PET) images 
of a patient before ( top panels ) and 8 hours after ( bottom panels ) imatinib 
treatment ( left panels: coronal view;  right panels: sagittal view) showing two 
rectal gastrointestinal stromal tumors behind the bladder and a liver metastasis. 
All tumors showed reduced uptake of tracer at 8 hours. Courtesy of Dr. H. Minn, 
University of Turku, Finland; reproduced by permission of Taylor & Francis Ltd. 
(http://www.tandf.co.uk/journals) from Joensuu et al.  ( 123 ) .  H ) [ 11 C]Thymidine 
scans of a patient with Ewing’s sarcoma ( i ) before and ( ii ) after combination 
chemotherapy. The  white areas indicate regions of highest tracer uptake. 
Combination chemotherapy resulted in decreased uptake of radiolabel. Resection 
revealed almost complete histologic response. Redrawn from Gupta et al.  ( 111 ) , 
reprinted with permission from Elsevier. GPC = glycerophosphocholine; GPE = 
glycerophosphoethanolamine; PC = phosphocholine; PCr = phosphocreatine; 
PME = phosphomonoester; Pi = inorganic phosphate; ppm = chemical shift in 
parts per million; NTP = nucleoside triphosphate. 
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those in animals, can extend over a concentration range of only 
approximately 1 order of magnitude. Nevertheless, if a fl uorine- 
or phosphorus-containing drug is in clinical trials, consideration 
should be given to including MRS studies in the trial. The sensi-
tivity of MRS is not a serious limitation for PD studies that 
involve the detection of endogenous metabolites present in mil-
limolar concentrations, such as lactate, ATP, phosphomonoesters, 
or phosphodiester compounds. Recent developments in hyperpo-
larization  ( 102 ) show considerable potential for increasing the 
sensitivity of MRS PK studies. 
 Table 1 summarizes methods currently available in magnetic 
resonance that could be applied in the development of a new 
drug. As an example of this approach, it is possible to hypothe-
size that applications 1, 4, 5, 6, and 9 could be used together to 
provide surrogate markers for use in clinical trials of a novel 
fl uorinated antimetabolite drug active at high doses ( ≥ 0.5 g/m 2 ) 
 Fig. 4.  Detecting apoptosis and cell death.  A )  31 P magnetic resonance spectra of 
extracts from ( a ) control untreated murine lymphocytic leukemia L1210 cells 
and ( b ) L1210 cells after 3 hours of treatment with 50 µM alkylating nitrogen 
mustard mechlorethamine (HN2), showing early metabolic effects of apoptotic 
cell death. Spectra are the result of 10  000 scans plotted with a line broadening of 
0.5 Hz. First published in Ronen et al.  ( 79 ) . DHAP = dihydroxyacetone phosphate; 
GP = glycerol-3-phosphate; fructose 1,6bisP = fructose 1,6-bisphosphate; ref = 
reference line (methylenediphosphonic acid); PE = phosphoethanolamine; PC = 
phosphocholine; Pi = inorganic phosphate; NTPs = nucleotide triphosphates 
(including nucleotide di-phosphates); NAD = nicotinamide-adenine dinucleotide. 
 B ) In vivo stimulated-echo acquisition mode ( a and  b ) and localization by adiabatic 
selective refocusing ( c and  d ) spectra from rat brain BT4C gliomas. These water-
suppressed  1 H nuclear magnetic resonance spectra were obtained from a tumor 
volume preselected from T2-weighted magnetic resonance images (not shown). 
Cr = creatine; Glx = glutamate and glutamine; Gly = glycine; Lac = lactate; mI = 
myo-inositol; Tau = taurine; ppm  – chemical shift in parts per million. In  c , lipid 
peaks are assigned according the chemical groups giving rise to the resonance. 
In  b and  d , the spectra are referenced to a fi xed height of the choline (CHO)-
containing metabolite peak. Day 0, Day 2, etc., refer to days 0 (pretreatment) 
through 8 of ganciclovir treatment. Reproduced with permission from Lehtimaki 
et al.  ( 81 ) .  C )  124 I-Annexin V distribution in vivo. Positron emission tomography 
images ( left ) and corresponding liver high-pressure liquid chromatography traces 
( right ) of an untreated mouse ( top panels ), an anti-Fas-treated mouse ( middle 
panels ) both 2 hours after intravenous injection with 5 MBq  124 I-annexin V and 
(at bottom) an treated anti-Fas-treated mouse 2 hours after intravenous injection 
with 5 MBq  124 I-ovalbumin. Mice injected with  124 I-annexin V were given 
potassium iodide intraperitoneally 2 hours before radioligand injection. The mouse 
injected with  124 I-ovalbumin received oral potassium iodide for 4 days before 
radioligand injection. Anesthesia was maintained with halothane (3% – 3.5%, 
2 L/min) and image data were acquired for approximately 1 hour. Reprinted from 
Keen et al.  ( 140 ), with permission from Elsevier .  
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 Fig. 5.  Monitoring hypoxia.  A ) Measurements of the hypoxia marker SR-4554. 
 i ) Magnetic resonance image of a patient showing a leiomyosarcoma of the left 
thigh (T2-weighted image).  ii – iv )  19 F magnetic resonance spectra (MRS) of the 
tumor acquired from the same patient at ( ii ) 2.18 hours, ( iii ) 7.98 hours, and 
( iv ) 27.50 hours after the start of SR-4554 infusion (1600 mg/m 2 ). Unlocalized 
spectra were acquired using a 10-cm surface coil and a 1.5-T magnetic resonance 
system (2048 transients acquired over 34 minutes, repetition time 1 second). 
 v ) Quantifi cation of the  19 F signal detected from the tumor at time points after 
the start of the intravenous infusion at a dose of 1600 mg/m 2 with an infusion 
time of 63 minutes. The graph compares concentrations of SR-4554 detected by 
 19 F MRS in the tumor, in which a fraction may be bound in hypoxic tissues and 
thus not be cleared as rapidly as in plasma, and the concentrations of the parent 
SR-4554 in plasma detected by ultraviolet high-pressure liquid chromatography 
(HPLC). Reproduced from Seddon et al.  ( 87 ) .  B ) [ 18 F]Fluoroetanidazole –
 positron emission tomography images of HT1080 human fi brosarcoma tumor-
bearing mice acquired on the small-animal quad-HiDAC scanner (cubic voxels 
of side: 0.5 mm).  a ) Three-dimensional (volume-rendered) image of an HT1080/
1-3C tumor-bearing mouse (showing data acquired over the period 30 – 60 minute 
postinjection) showing a dorsal view of the mouse. Here, pixel values are defi ned 
by the maximum voxel value in corresponding lines in the z-axis.  Arrows point to 
tumor (Tm), kidneys (Ki), small intestine (In), and urinary bladder (Bl).  b ) Sagittal 
(0.5 mm) slice of data acquired over the period 30 – 60 minutes postinjection from 
the same mouse as in ( a ) at the midplane level, showing low radiotracer uptake in 
brain (Br) and spinal cord (Co), as well as high accumulation in urinary bladder. 
 c ) Transverse (0.5 mm) slice of data acquired over the period 30 – 60 minutes 
postinjection from the same HT1080/1-3C tumor-bearing mouse as in ( a ) at the 
level of the maximal tumor diameter.  d ) Corresponding transverse slice from an 
HT1080/26.6 tumor-bearing mouse, exhibiting lower tumor radiotracer uptake. 
The scale to the right shows uptake in arbitrary units. First published in Barthel 
et al.  ( 138 ) . 
that inhibits cell proliferation and the growth of solid tumors. 
MRS methods for PK can be used at a late preclinical stage and 
in phase I and II trials, either in situ for liver and tumor or ex vivo 
for analysis of body fl uids and tumor biopsies. These studies 
could establish whether minimal effi cacious doses actually reach 
the tumor and, if appropriate, whether the drug is metabolized to 
cytotoxic species. In clinical trials, MRI-based PD methods could 
determine whether the drug had a measurable effect on tumor 
size, functional volume, permeability, or perfusion. However, 
these MRI studies could be preceded by  1 H- and/or  31 P-MRS to 
measure changes in energy metabolism, pH, and choline metabo-
lism before effects on tumor size become apparent. These PD 
MRS techniques could also eventually be used routinely in the 
clinic to permit early detection of nonresponding tumors. For 
responding tumors, these PD MRS techniques could be used in 
conjunction with PK assays to optimize treatment (e.g., dose 
scheduling). MRS can also provide measures of specifi c molecu-
lar processes in vivo. For example, an increase in fructose-1,6-
bisphosphate concentration is a sensitive measure of apoptosis in 
some in vitro cell systems. It is apparent early in the apoptotic 
process and is believed to refl ect poly(adenosine diphosphate-
ribose) polymerase activation ( Fig. 4, A )  ( 103 ) . Ras activation 
can lead to increased levels of phosphocholine  ( 104 ) . Pharmaco-
logic blockade of Ras signaling with prototype mitogen-activated 
protein kinase kinase 1/2 (MEK1/2) inhibitors leads to a decrease 
in the phosphocholine signal that is associated with inhibition of 
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation 
 ( 105 ) . The heat shock protein inhibitor 17-allylamino,17-deme-
thoxygeldanamycin (17AAG) increases levels of phosphomonoes-
ters and phosphodiesters in cancer cells and in human tumor 
xenografts ( Fig. 3, E – F )  ( 106 ) . These markers are currently being 
evaluated in phase I and II clinical trials of 17AAG. 
 Increases in the magnetic fi eld (and thus sensitivity) of MRS 
instruments are addressing the method’s sensitivity problem. Use 
of the higher fi eld MRS systems (2.0 – 8.0 T) now available for 
clinical research will substantially improve the sensitivity limits 
of MRS. Preclinical studies are typically performed at 4.7 – 11.8 T. 
MRS scans of brain tumors with the current generation of 1.5-T 
instruments can be carried out during routine MRI examinations 
and take only about 20 minutes. Studies on anticancer drugs usu-
ally take longer; a typical scan lasts approximately 30 minutes, 
and longer scans may be necessary to obtain useful PK param-
eters. Recommendations for standardization of clinical MRS 
measurements, based on an international workshop, have been 
published  ( 107 ) . 
 MRI already plays an important role in conventional assess-
ments of response to therapy. The ability to complement highly 
detailed morphologic information with information on  function 
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and metabolism provides a powerful tool for assessing novel 
mechanism-based therapeutics in both the preclinical and clin-
ical settings. Although magnetic resonance has limited sensi-
tivity for direct PK assessments (see  Table 1 ), its chemical 
specifi city allows drugs and metabolites to be identifi ed, so 
that in the future, it may be possible to radically improve sen-
sitivity by using hyperpolarization techniques  ( 108 ) . The spec-
ifi city of MRI techniques in PD assessment is also likely to 
grow as new families of biologically targeted contrast agents 
are developed  ( 109 ) . 
 Fig. 6.  Complementary modalities used to observe drug pharmacokinetics and 
metabolism in patients.  A ) Time course of uptake of the antimetabolite 5-fl uorouracil 
(5FU) in the liver and metastases of a 73-year-old male with colorectal cancer 
showing conversion of 5FU to fl uoro- β -alanine (FBAL). Courtesy of Professor J. 
Griffi ths, St. Georges Hospital Medical School.  B ) Summed time course data from 
( A ) showing the anabolite fl uoronucleotides (FNuct) as well as 5FU and FBAL. 
C ) Two-dimensional magnetic resonance spectroscopic map of the liver super-
imposed on a proton image showing drug metabolite signal localized to the 
gallbladder. Reproduced with permission from Dzik-Jurasz et al.  ( 101 ) .  D ) Che-
mical specifi city of the localized metabolite signals from ( C ):  i ) unlocalized signal 
from whole liver,  ii ) spectrum from a voxel positioned in liver,  iii ) spectrum 
from a voxel localized in the gallbladder, showing a shift in the resonant frequency 
of the FBAL in the gallbladder ( left-hand arrow ) due to conjugation with bile 
acid compared with unconjugated FBAL in the liver ( right-hand arrow ). 
Reproduced with permission from Dzik-Jurasz et al.  ( 101 ) .  E ) Positron emission 
tomography images of  18 F-labeled 5FU at two time points after administration 
to ( i ) eniluracil-naive patients and ( ii ) eniluracil-treated patients. Eniluracil de-
creases catabolic breakdown of 5FU, reducing clearance of drug in the liver 
with metabolism predominantly via the anabolic pathway. High levels of drug 
are shown as  white , low levels are dark  red . Modifi ed from Saleem et al.  ( 113 ) , 
reprinted with permission from Elsevier. 
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 P OSITRON E MISSION T OMOGRAPHY 
 PET allows dynamic, noninvasive measures of the three-
dimensional distribution of a positron-labeled compound within 
the living body. After injection of a labeled compound, the radio-
isotope decays and emits a positron that travels a short distance 
and is annihilated by colliding with an electron. The annihilation 
produces two 511-keV photons, which propagate at an approxi-
mate 180° angle away from each other and can be detected within 
a short time (typically 19 nanoseconds). The summation of many 
such events provide the distribution of the radiotracer. Both tu-
mor and normal tissues (including liver, brain, heart, vertebrae, 
spleen, kidney, and muscle) in the fi eld of view can be evaluated 
 ( 110 ) . Over the past few years, there has been a major increase in 
the use of PET in oncology  ( 111 ) . There are now several exam-
ples in which the capabilities of this technology in anticancer 
drug development have been demonstrated in terms of PK and 
PD ( Table 1 ). 
 PET can be used to evaluate intratumoral and normal tissue PK 
in patients prior to phase I studies (pre-phase I) or as part of phase 
I and II studies ( Fig. 6 E )  ( 112 ) . This objective can be achieved by 
labeling the drugs of interest with positron-emitting isotopes such 
as  11 C,  18 F,  124 I, or  13 N. The chemical identities and, hence, the 
physicochemical properties of drugs are retained following radio-
labeling. Typical examples of drugs that have been evaluated by 
PET in patients include  18 F-5FU  ( 113 ) ,  11 C-temozolomide  ( 114 ) , 
 13 N-cisplatin  ( 115 ) ,  11 C-1,3-bis(2-chloroethyl)-1-nitrosourea 
( 11 C-BCNU)  ( 116 ) ,  18 F-tamoxifen  ( 117 ) , and  11 C-N-[2-(dimethyl-
amino)ethyl]acridine-4-carboxamide ( 11 C-DACA)  ( 118 ) . In the 
case of temozolomide, the proposed mechanism of action of the 
drug, involving DNA methylation, was evaluated in patients by 
using  11 C-temozolomide tracers labeled at the methyl and car-
bonyl positions  ( 119 ) . That study demonstrated that temozolo-
mide undergoes tissue-specifi c ring-opening in humans, although 
this conformational change was not tumor-specifi c. Preclinical 
labeling and PET imaging of macromolecules such as  18 F-labeled 
antisense oligonucleotides is currently being pursued  ( 120 ) . 
 Despite the increasing number of potential radiotracers in on-
cology (see  Table 1 ), PET is still generally synonymous with 
 18 FDG imaging because most centers worldwide employ this ra-
diotracer for diagnostic imaging. However, changes in  18 FDG 
uptake refl ect infl ammatory responses as well as tumor response 
but make  18 FDG imaging less specifi c for general use. Changes 
in  18 FDG uptake can occur within hours after treatment or can 
take several days to weeks, as a result of cell death. For example, 
in patients with gastrointestinal stromal tumors who are treated 
with imatinib  ( 121 ) , early changes in  18 FDG presumably refl ect 
the direct effect of imatinib on glucose metabolism  ( Fig. 3, G ) 
 ( 122 , 123 ) . 
 PD studies that can be performed by PET can be grouped into 
those that employ generic versus specifi c biologic endpoints. 
In the case of studies that employ generic endpoints, opportunities 
exist for monitoring changes in cellular proliferation with 
 11 C-thymidine ( Fig. 3, H )  ( 111 , 124 ) , glucose utilization with  18 FDG 
 ( 125 ) , tissue perfusion with  15 O-H 2 O  ( 126 ) , and blood volume 
with  15 O-CO  ( 127 ) . A less readily metabolized analog of  11 C-
thymidine,  18 fl uorothymidine, can be used to monitor DNA syn-
thesis and cellular proliferation  ( 128 ) . Other generic endpoints 
that have been monitored by PET include amino acid metabolism 
with  11 C-methionine  ( 129 ) or methyl-fl uoro-dopa  ( 130 ) and 
tricarboxylic acid cycle activity with  11 C-acetate  ( 131 ) . We 
envisage that evaluation of these generic endpoints will be 
used increasingly to assess the effects of novel therapeutics in the 
future. 
 Specifi c biologic endpoints are undergoing preclinical and 
clinical validation to provide proof of principle for the proposed 
mechanism of action of existing and novel therapies. Examples 
of such endpoints include detection of thymidylate synthase in-
hibition with  11 C-thymidine  ( 132 ) ; detection of VEGF or VEGF 
receptor expression with  124 I-labeled antibodies and peptides 
( Fig. 2, C )  ( 133 , 134 ) ; detection of overexpression of ErbB2 
receptors with  68 Ga-labeled anti-ErbB2 antibody  ( 135 ) ; evalua-
tion of estrogen receptor status with 16- α - 18 fl uoro-17- β -estradiol 
 ( 136 ) ; detection of hypoxia with  18 fl uoromisonidazole  ( 137 ) , 
other  18 F-labeled 2-nitroimidazoles ( Fig. 5, B )  ( 138 ) , and  60 Cu-
based probes  ( 139 ) ; imaging of apoptosis with  124 I-annexin V 
by PET ( Fig. 4, C  ( 140 ) and  99m Tc-hydrazinonicotinyl ( 99m Tc-
HYNIC) annexin V single-photon emission computed tomogra-
phy (SPECT)  ( 141 – 144 ) ; and imaging of alpha-V-beta-3 integrin 
receptor expression with  18 F- and  64 Cu-arginine-glycine-aspartate 
(RGD)-based peptides  ( 145 , 146 ) . With the advent of several 
gene therapy approaches, PET methods are also being developed 
to monitor gene expression in vivo. Most of those methods 
employ a marker gene, such as those encoding the Herpes 
simplex virus 1-thymidine kinase, the dopamine D2 receptor, 
or the sodium iodide symporter, and a marker substrate, such 
as  124 I-2 ′ -fl uoro-5-iodo-1- β - d -arabinofuranosyluracil (FIAU), 
3-(2 ′ - 18 fl uoroethyl)spiperone, or Na 124 I, respectively  ( 147 – 150 ) . 
In this way, proof that these reporter – substrate pairs detect gene 
expression has been demonstrated in human tumor xenograft 
models  ( 147 – 150 ) and in patients with recurrent glioblastomas 
 ( 151 ) . In addition, PET methods are currently being developed 
for monitoring drug resistance. For instance,  11 C-daunorubicin – 
and  11 C-verapamil – PET have been employed to monitor the 
P-glycoprotein – mediated multidrug resistance phenotype in 
rodent tumors  ( 152 ) . 
 Although PET imaging has many advantages for use in drug 
development, it is important to be aware of its limitations 
 ( Table 1 ). Not all compounds (i.e., drugs or biochemical probes) 
can be radiolabeled. Each compound must be considered on an 
individual basis as a candidate for labeling. Small molecules, 
proteins, and antibodies can be selectively radiolabeled if suit-
able functional groups are present. Labeling can be performed to 
obtain a chemically identical compound that contains  11 C or  18 F, 
if fl uorine is present in the original molecule (e.g., 5FU and gefi -
tinib). Compounds with N-, S-, or O-methyl or ethyl groups, as 
well as proteins and antibodies, can be labeled fairly easily. How-
ever, not all drugs can be labeled, for the following reasons: 1) in 
some cases, the multistep chemistry required for labeling pre-
cludes radiolabeling and purifi cation of molecules rapidly enough 
to avoid substantial decay of radioactivity; 2) suitable precursors 
for radiolabeling a number of compounds (especially natural 
products) may not be available, a problem that may be alleviated 
by including precursor strategies into development programs; 
and/or 3) the position of the label may not be robust to metabolic 
degradation. However, this latter issue can occasionally be turned 
into an advantage for studying the mechanism of drug action as, 
for example, in the case of demonstrating the mechanism of 
action of temozolomide in patients  ( 119 ) . 
 Regarding imaging data, PET images have low anatomic 
 resolution; hence, it is common practice to align PET data with 
data from MRI and CT. The development of integrated PET – CT 
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systems may reduce the extent of the poor anatomic resolution of 
PET images  ( 153 ) . PET is also limited by a lack of chemical 
resolution; i.e., unlike MRS, PET cannot distinguish between the 
parental radiotracer and its labeled or unlabeled metabolites. This 
is not a problem for drugs that are not metabolized extensively. 
However, for extensively metabolized drugs, which may include 
more than 95% of all compounds, metabolism can complicate the 
interpretation of PET data, requiring complex mathematical 
modeling for data analysis. Strategies to prevent the retention of 
labeled metabolites in tissues have been developed, for example, 
labeling compounds in such a way that metabolites are exhaled 
as  11 CO 2 , as well as tissue  11 CO 2 correction methodologies  ( 154 ) . 
In cases in which tracers with longer half-lives are employed 
(e.g., FIAU), confounding of signal analysis by labeled metabo-
lites can be overcome by a  “ washout ” strategy, in which nonspe-
cifi c metabolites are eliminated while specifi cally bound species 
that can be imaged at a late time point are retained. 
 Most of the PET isotopes mentioned above have short to 
moderate physical half-lives (e.g.,  15 O = 2 minutes,  13 N = 10 
minutes,  11 C = 20 minutes,  18 F = 110 minutes, and  124 I = 4 days). 
For some positron-labeled compounds, the combination of a 
short physical half-life and a short biologic half-life can limit 
the type of pharmacologic information that can be attained. 
However, for patient comfort, imaging times should be limited 
to 1 – 3 hours. Although it is preferable to use longer-lived iso-
topes to label radiotracers that have relatively long biologic 
half-lives, it is also important to consider the measured radiation 
dose to specifi c organs and to the whole body. Radiation expo-
sure is a potential limitation of PET radioisotopes, particularly 
when PET or PET – CT imaging studies are performed on multi-
ple occasions. 
 Various physical processes limit the spatial resolution attain-
able with PET to 2 – 3 mm for clinical scanners (4.6 – 8 mm for 
most currently available commercial scanners) and to 1 mm for 
animal scanners. However, the sensitivity of this technique 
( ~ 10  − 12 M) and the time for kinetic resolution are extremely high. 
Finally, PET scanning is expensive because it includes the costs 
of labeling the compound, quality control, the radiographer’s 
time, and modeling of the data. For these reasons, most centers 
worldwide usually concentrate on PET scanning using only one 
or two tracers. Few centers have a comprehensive range of fa-
cilities, including cyclotrons, radiochemistry hot-cells, and PET 
scanners, and personnel, including radiographers, staff for phys-
ics and mathematical modeling support, as well as nonclinical 
and clinical researchers. 
 With the availability of dedicated small-animal scanners, 
which are desirable for generating preclinical validation data 
 ( 155 ) , there is great potential to develop and test new therapeutics 
in disease models of cancer using PET. For instance, PET can be 
used to study gene expression over time in a tumor- bearing or 
transgenic animal, potentially providing data that could bridge the 
gap between basic science and clinical application. There is also 
the potential to develop PET imaging strategies for studying 
 protein – protein and DNA – oligonucleotide interactions, apoptosis, 
signal transduction inhibition, and  ligand – receptor  interactions. 
 Many PET centers in developed countries have the capability 
to undertake clinical  18 FDG studies to evaluate responses to anti-
cancer agents. A few centers can also perform preclinical PET 
studies. However, substantial resources will need to be invested 
to support clinical facilities if PET is to play a key, routine role in 
anticancer drug development. 
 As PET becomes a common tool for studying molecular in-
teractions in humans, guidelines for its use in clinical and labo-
ratory practice are needed. This need is partly being addressed 
by the EORTC Functional Imaging Group with the publication 
of guidelines for  18 FDG response assessment  ( 122 ) . Guidelines 
on pre-phase I toxicology of cancer therapeutic and diagnostic 
agents for use with PET research have been published by the 
Working Party on PET Pre-Phase I trials of Cancer Research 
UK  ( 156 ) . 
 There is enormous potential for the use of PET in the assess-
ment of tissue PK or PD endpoints. Like MRI and MRS, PET is 
minimally invasive and can be used repeatedly in the same sub-
ject, thus avoiding the need for multiple biopsies. Although PET 
has some limitations, such as its lack of chemical resolution and 
the limited half-life of many isotopes ( Table 1 ), its potential in 
drug development is enormous and we anticipate that this tech-
nology will be used increasingly to provide information on 
whether the drug reaches desirable concentrations in tumors, 
modulates a particular molecular target, and affects the desired 
biologic activity  ( 15 ) . 
 C ONCLUSIONS 
 Because of our increasingly detailed understanding of the ge-
nomics and molecular biology of cancer, enormous expectations 
are being placed on the development of new molecular therapeu-
tics that exploit this growing knowledge. Although there have 
been a small number of impressive successes (e.g., imatinib and 
trastuzumab), there have also been many high-profi le failures 
(e.g., gefi tinib in combination with chemotherapy). The under-
standable impatience of the public and of the academic and 
pharmaceutical communities to rapidly translate our comprehen-
sion of the molecular biology of cancer into genuine therapeutic 
advances creates an inevitable tension when coupled to the rela-
tively small number of successes in drug development  ( 157 ) . The 
identifi cation and implementation of PK/PD endpoints provide a 
powerful mechanism for improving the quality of drug develop-
ment, allowing prioritization of the drugs that are most likely to 
succeed, accelerating their regulatory approval, and reducing the 
overall risks and costs of pharmaceutical development  ( 15 – 19 ) . 
 As a recent survey has shown, the uptake of PK/PD and bio-
marker endpoints in early clinical trials has been surprisingly and 
disappointingly poor  ( 20 ) . This low uptake may relate to the 
challenges in bringing forward appropriate methodologies that 
have a genuine impact on decision making rather than being 
purely  “ decorative ”  ( 22 ) . The added value provided by PK/PD 
methodologies must exceed their potential negative impact on 
the cost, logistics, and speed of clinical trials. The methodology 
must be made available and be appropriately validated so that it 
can be implemented in a timely way to maximize its value for 
decision making. We feel that there has been an underinvestment 
in PK/PD endpoints and that, in cases where they are available, 
they have not been implemented effi ciently. The technical chal-
lenges and logistic considerations mentioned above, coupled 
with suboptimal sharing and communication of information, 
risks, and benefi ts among the academic, pharmaceutical, and 
regulatory communities, are also likely to contribute to the infre-
quent implementation of PK/PD endpoints  ( 19 ) . Although recog-
nition of these issues has improved recently in pharmaceutical 
development in general  ( 158 – 161 ) and in oncology in particular 
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 ( 15 , 19 ) , the benefi ts are not yet readily apparent  ( 20 ) . Communi-
cation of experience and the development of guidelines for 
PK/PD endpoints are therefore critically important. 
 It is against this general background and the particular experi-
ence of the New Agents Committee and Drug Development 
 Offi ce of Cancer Research UK that the required endpoints were 
frequently not in place and/or validated, that we decided to sum-
marize and communicate our emerging experience. Although this 
review is written from a U.K. perspective, we feel that our expe-
rience will be relevant to other drug development organizations, 
and we welcome feedback from the broader oncology commu-
nity. Of note, the U.S. Food and Drug Administration published 
a draft guidance for industry, investigators, and reviewers for ex-
ploratory investigational new drug studies, which describes the 
proposed requirements for early, limited clinical investigations 
intended to assess the feasibility for further development of a 
drug or biologic product  ( 162 ) . In particular, the guidance refers 
to imaging studies and the concept of dose escalation to a 
 predefi ned PD endpoint. The present review was focused on 
 minimally invasive PK/PD endpoints because these methods over-
 come many (although not all) of the logistical and ethical issues 
that are associated with invasive measurements. In particular, 
the technologies we discuss avoid the need for studying surrogate 
markers in multiple blood samples or normal tissue or tumor 
biopsy samples. We emphasize, however, that the use of biopsy 
and other invasive surrogate-based assays to measure PK and PD 
remains an important component of early clinical trials. For ex-
ample, invasive assays to measure direct target modulation could 
usefully complement the minimally invasive imaging of down-
stream effects such as inhibition of cell proliferation or induction 
of apoptosis. We have emphasized MRS/MRI and PET methods 
because they are increasingly available and provide more de-
tailed functional and metabolic information than many other 
methodologies. In addition to the methods reviewed here, other 
imaging methods, such as bioluminescence and fl uorescence/
infrared, can be used preclinically to confi rm the mechanism of 
action of new drugs but cannot be used clinically to evaluate the 
agents  ( 163 – 165 ) . Such methods can be designed to specifi cally 
monitor receptor activity, protein – protein interactions, and 
 transcriptional activity and may add value to the other methods 
described in this review. 
  A central role of PK/PD endpoints is to contribute informa-
tion to allow the construction of the pharmacologic audit trail 
that links, as far as is realistically possible, all of the molecular 
and biologic events from the action of the drug at its target locus 
to the demonstration of clinical activity and benefi t  ( 15 – 17 ) . In 
general, there is a greater need for PD biomarkers of drug effect. 
Although PK measurements are routinely made on the plasma 
compartment, information is often lacking on drug distribution 
and metabolism in normal and tumor tissue. This information can 
be provided by MRS/MRI and PET  ( 93 , 166 ) . 
 There are several examples in which the use of noninvasive 
PK and PD endpoints have had a positive impact on, and added 
real value to, early clinical trials of innovative therapies. The 
use of  18 FDG PET allowed the rapid demonstration of the dra-
matic activity of imatinib in gastrointestinal stromal tumors 
 ( 167 ) . Cell proliferation measurement with tracers such as 
 18 fl uorothymidine are also valuable  ( 168 , 169 ) . The combina-
tion of PET and CT provides metabolic measurements with op-
timal spatial resolution, which is a major advantage of such 
noninvasive methods  ( 170 ) . PET and MRI have each proven 
valuable in assessing the functional activity of antiangiogenesis 
and antivascular strategies. For example, these methods were 
used to demonstrate the effects of combrestatin A4 phosphate 
on blood fl ow  ( 171 – 173 ) . An editorial  ( 22 ) that accompanied 
the publication of those studies concluded that imaging assisted 
the selection of doses for phase II studies, albeit fairly margin-
ally; that it provided help with the selection of the best schedule 
for phase II studies; and that it could potentially be used to se-
lect subpopulations of patients who respond to the drug. The 
same editorial also emphasized that both MRI and PET meth-
ods for measuring  tumor blood fl ow were becoming more 
widely available and that the current technical limitations ap-
parent in 2003 should not drive readers to conclude that the 
technology is impractical. 
 Noninvasive imaging methodologies have clearly proved 
valuable in studies that have generally involved measuring events 
downstream of the molecular target in the previously discussed 
pharmacologic audit trail ( Fig. 1 ). Whereas invasive monitoring 
with molecular analysis has, in some cases, been useful in dem-
onstrating proof of concept and in selecting the dose and sched-
ule for molecular therapeutics such as kinase and histone 
deacetylase inhibitors  ( 174 – 176 ) , the equivalent information is 
not yet readily achievable with imaging technologies. However, 
it has been possible to determine receptor status by PET 
 ( 135 , 136 , 145 , 146 ) . Much greater effort needs to be put into de-
veloping probes and technologies to detect and quantify specifi c 
molecular events. 
 On the other hand, although noninvasive imaging methods 
to measure specifi c molecular target effects, such as enzyme 
inhibition or protein – protein interactions, would be desirable, 
these methods would have to be developed individually for 
each class of therapeutic agent. It could be argued, however, 
that this may not be the best use of available resources, given 
the high attrition rates of individual drugs  ( 157 ) . According to 
this notion, it may be preferable to give priority to the develop-
ment of generic assays that measure the common biologic 
processes that are affected by many different drug classes, par-
ticularly proliferation, cell cycle status, apoptosis, invasion, 
metastasis, and angiogenesis. 
 S UMMARY 
 The development of assays for patient selection will become 
increasingly important  ( 177 , 178 ) . The development of PK and in 
particular PD endpoints that allow construction of the pharmaco-
logical audit trail is essential  ( 14 – 18 ) . Although the use of mini-
mally invasive endpoints that measure interaction at specifi c 
molecular targets will be valuable and is encouraged for research 
purposes, this is technically challenging, and greater cost/benefi t 
will be derived from developing assays for biological processes 
that will be more generically applicable to different classes of 
molecular therapeutics. We recommend that funding bodies and 
industry should invest more in the development, validation and 
standardization of minimally invasive methodologies as well as 
in the development of instrumentation. Quality assurance is im-
portant, especially across institutions participating in multicenter 
clinical trials, and standardized methodology and nomenclature 
should be employed  ( 47 , 107 , 122 , 156 ) . Finally, attention needs to 
be paid to differences in study objectives for research investiga-
tions versus regulatory and commercial requirements. 
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